Demographics and patient characteristics
| Characteristic . | Enoxaparin (N = 104) . | Controls (N = 189) . |
|---|---|---|
| Males, n (%) | 55 (52.9%) | 94 (49.7%) |
| Mean age at time of brain metastasis, y (range) | 60.9 (31.1-84.6) | 60 (21.9-92.1) |
| Stage 4 at time of cancer diagnosis, n (%) | 46 (44.2%) | 91 (48.1%) |
| Number of brain lesions when first recognized, n (%) | ||
| 1-2 | 63 (60.6%) | 107 (56.6%) |
| 3-4 | 10 (9.6%) | 29 (15.3%) |
| 5 or more | 16 (15.4%) | 25 (13.2%) |
| Primary malignancy, n (%) | ||
| Non-small cell lung cancer | 56 (53.8%) | 97 (51.3%) |
| Breast cancer | 12 (11.5%) | 25 (13.2%) |
| Renal cell carcinoma | 10 (9.6%) | 20 (10.6%) |
| Melanoma | 10 (9.6%) | 20 (10.6%) |
| Colorectal cancer | 5 (4.8%) | 9 (4.8%) |
| Small cell lung cancer | 2 (1.9%) | 6 (3.2%) |
| Comorbidities, n (%) | ||
| Hypertension | 40 (38.5%) | 76 (40.2%) |
| Chronic kidney disease | 5 (4.8%) | 18 (9.5%) |
| Treatment of brain metastasis, n (%) | ||
| Chemotherapy after brain met diagnosis | 72 (69.2%) | 115 (60.8%) |
| Brain radiation* | 82 (78.8%) | 163 (86.2%) |
| Neurosurgery | 30 (28.8%) | 44 (23.3%) |
| Corticosteroids for cerebral edema | 74 (71.2%) | 162 (85.7%) |
| Neurosurgery or brain radiation | 83 (79.8%) | 168 (88.9%) |
| Concomitant medications | ||
| Aspirin use, n (%) | 5 (4.8%) | 29 (15.3%)† |
| Antiangiogenic agents | 14 (13.5%) | 10 (5.2%)‡ |
| Characteristic . | Enoxaparin (N = 104) . | Controls (N = 189) . |
|---|---|---|
| Males, n (%) | 55 (52.9%) | 94 (49.7%) |
| Mean age at time of brain metastasis, y (range) | 60.9 (31.1-84.6) | 60 (21.9-92.1) |
| Stage 4 at time of cancer diagnosis, n (%) | 46 (44.2%) | 91 (48.1%) |
| Number of brain lesions when first recognized, n (%) | ||
| 1-2 | 63 (60.6%) | 107 (56.6%) |
| 3-4 | 10 (9.6%) | 29 (15.3%) |
| 5 or more | 16 (15.4%) | 25 (13.2%) |
| Primary malignancy, n (%) | ||
| Non-small cell lung cancer | 56 (53.8%) | 97 (51.3%) |
| Breast cancer | 12 (11.5%) | 25 (13.2%) |
| Renal cell carcinoma | 10 (9.6%) | 20 (10.6%) |
| Melanoma | 10 (9.6%) | 20 (10.6%) |
| Colorectal cancer | 5 (4.8%) | 9 (4.8%) |
| Small cell lung cancer | 2 (1.9%) | 6 (3.2%) |
| Comorbidities, n (%) | ||
| Hypertension | 40 (38.5%) | 76 (40.2%) |
| Chronic kidney disease | 5 (4.8%) | 18 (9.5%) |
| Treatment of brain metastasis, n (%) | ||
| Chemotherapy after brain met diagnosis | 72 (69.2%) | 115 (60.8%) |
| Brain radiation* | 82 (78.8%) | 163 (86.2%) |
| Neurosurgery | 30 (28.8%) | 44 (23.3%) |
| Corticosteroids for cerebral edema | 74 (71.2%) | 162 (85.7%) |
| Neurosurgery or brain radiation | 83 (79.8%) | 168 (88.9%) |
| Concomitant medications | ||
| Aspirin use, n (%) | 5 (4.8%) | 29 (15.3%)† |
| Antiangiogenic agents | 14 (13.5%) | 10 (5.2%)‡ |